Lucid Motors is a long-term winner, but CCIV stock does not represent Lucid Motors' promising business... yet.
Science fiction collides with reality, as exoskeletons become a real-world device with a number of applications.
There are only a handful of large, well-established gene editors with robust and mature therapy pipelines in the world today. Of those, one that stands out is a $4.8 billion biotechnology company by the name of Editas Medicine (NASDAQ:EDIT).
Today, we will tell you about another name you can add to your list of “EV charging station stocks to buy.” It’s a longtime EV charging industry leader that is well-positioned to leverage its leading tech portfolio and network effects…
Netflix's Q4 earnings were such a home-run hit that they could juice a 40% rally in NFLX stock over the next year.